This bill, known as the "Reducing Hereditary Cancer Act," aims to significantly expand Medicare coverage for services related to hereditary cancer. Its primary goal is to improve early detection and prevention for individuals at high risk due to genetic predispositions. Specifically, the legislation mandates Medicare coverage for germline mutation genetic testing for individuals with a personal or family history of a hereditary cancer gene mutation, or a history otherwise suspicious for hereditary cancer. This testing must adhere to evidence-based clinical practice guidelines developed by nationally recognized oncology professional organizations, with the least restrictive guidelines applying in cases of conflict. Furthermore, the bill requires Medicare to cover certain risk-reducing surgeries for individuals with inherited mutations where such surgery would reduce the risk of developing cancer, based on established clinical guidelines. It also increases the frequency limitations for evidence-based cancer screenings , such as mammography and colonoscopy, for individuals identified with a hereditary cancer gene mutation, ensuring they receive screenings at least annually or as recommended by guidelines.